Kentucky Medical Cannabis Licensing Process Reviewed
The Kentucky Finance and Administration Cabinet Office of the Inspector General (OIG) has concluded its investigation into the Kentucky medical cannabis licensing process, determining it to be “fully fair and transparent.” This finding was detailed in a May 7 report, which followed a request for investigation by the Kentucky Office of Medical Cannabis (OMC) over a year prior, according to a Louisville Courier Journal report. The review specifically addressed complaints that the lottery system for dispensary licenses disadvantaged smaller, in-state businesses.
Governor Andy Beshear commented on the report during a Team Kentucky Update, stating that the OIG’s findings recognized the OMC’s goals of fairness and transparency were met, as reported by WHAS11 News via Yahoo News. The OIG’s report stated, “After independently reviewing the program, the licensure process it created in regulation, and the relevant regulations and statutes, this office found that OMC created an effective program that was fully transparent and fair to all licensure applicants,” as cited by Ganjapreneur.
Investigation Scope and Findings
The OIG’s investigation focused on the circumstances surrounding the cannabis dispensary license lotteries and analyzed the applications of all companies that were selected for licenses. This approach was taken to maximize efficiency, rather than reviewing approximately 5,000 total applications. The review included:
- Reports and data analysis
- Process evaluations
- Review of footage and legislative testimony
- Interviews with individuals involved in the licensing process
The report concluded that the program “issued regulations in a fully transparent manner” after undergoing a full review by multiple legislative committees. It also noted that the licensure application process involved a thorough review for consistency, uniform flagging of issues, and opportunities for applicants to correct deficiencies before being eligible for the random lottery drawing.
The OMC also emphasized that the cabinet prioritizes applications from existing Kentucky hemp businesses in good standing with the Kentucky Department of Agriculture, provided they meet all application requirements and regulations.
Industry Concerns and Counter-Findings
Despite the OIG’s findings regarding the Kentucky medical cannabis licensing process, the lottery system, which began after an emergency regulation in April 2024, has drawn criticism. The system was initially intended to prevent conflicts and litigation while leveling the playing field for all businesses, including small enterprises, as stated by former Office of Medical Cannabis Executive Director Sam Flynn.
However, Kentucky farmers and business owners alleged that larger, out-of-state companies exploited loopholes in state law by submitting numerous applications to increase their odds of securing a license. These complaints prompted Kentucky Auditor of Public Accounts Allison Ball to launch a separate investigation. Ball’s preliminary findings indicated that at least one company managed to obtain business licenses across all categories, which state law was designed to prevent. Ball’s assessment suggested the current licensing process favors existing and out-of-state cannabis companies.
For instance, a Courier Journal investigation highlighted Arkansas-based Dark Horse Cannabis, which reportedly secured licenses across all three business categories, despite state law intending to limit companies to one category at a time. This situation has led several in-state medical cannabis businesses to file lawsuits, challenging the delegation of issuance limits and the creation of licensing districts as violations of Kentucky’s constitution.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
